Free Trial

Werewolf Therapeutics (HOWL) Competitors

Werewolf Therapeutics logo
$1.08 +0.01 (+0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$1.09 +0.01 (+0.93%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HOWL vs. CTMX, OGI, GNFT, FDMT, IPHA, VTYX, DERM, PBYI, DMAC, and SPRO

Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), 4D Molecular Therapeutics (FDMT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

Werewolf Therapeutics vs. Its Competitors

CytomX Therapeutics (NASDAQ:CTMX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

CytomX Therapeutics has a net margin of 28.22% compared to Werewolf Therapeutics' net margin of 0.00%. Werewolf Therapeutics' return on equity of -89.37% beat CytomX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CytomX Therapeutics28.22% -553.71% 32.21%
Werewolf Therapeutics N/A -89.37%-54.87%

In the previous week, Werewolf Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 2 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.75 beat Werewolf Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CytomX Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Werewolf Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CytomX Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

CytomX Therapeutics has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CytomX Therapeutics$138.10M1.52$31.87M$0.485.42
Werewolf Therapeutics$1.88M25.78-$70.51M-$1.67-0.65

CytomX Therapeutics presently has a consensus target price of $5.33, indicating a potential upside of 105.13%. Werewolf Therapeutics has a consensus target price of $8.33, indicating a potential upside of 671.60%. Given Werewolf Therapeutics' higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than CytomX Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Werewolf Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats Werewolf Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HOWL vs. The Competition

MetricWerewolf TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$48.01M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E RatioN/A8.0519.5820.23
Price / Sales25.78296.11442.27127.79
Price / CashN/A42.7337.5058.41
Price / Book0.657.748.085.60
Net Income-$70.51M-$54.96M$3.16B$248.43M
7 Day Performance-0.09%6.04%3.77%5.15%
1 Month Performance-18.80%4.47%3.90%7.62%
1 Year Performance-50.91%6.12%34.22%21.56%

Werewolf Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HOWL
Werewolf Therapeutics
3.0814 of 5 stars
$1.08
+0.9%
$8.33
+671.6%
-54.3%$48.01M$1.88M0.0040News Coverage
CTMX
CytomX Therapeutics
4.2022 of 5 stars
$2.27
+0.9%
$5.33
+134.9%
+84.4%$181.40M$138.10M4.73170News Coverage
OGI
Organigram Global
0.9872 of 5 stars
$1.35
flat
N/A-8.3%$180.82M$117.47M13.50860News Coverage
GNFT
GENFIT
2.0798 of 5 stars
$3.73
+3.2%
$13.00
+249.0%
-12.2%$180.49M$67.00M0.00120News Coverage
Positive News
FDMT
4D Molecular Therapeutics
2.1296 of 5 stars
$3.71
-3.4%
$29.56
+696.6%
-80.5%$177.89M$40K-1.17120
IPHA
Innate Pharma
2.5488 of 5 stars
$1.82
-1.9%
$11.00
+506.1%
-16.1%$170.53M$21.77M0.00220
VTYX
Ventyx Biosciences
3.0518 of 5 stars
$2.14
-8.5%
$10.00
+367.3%
+2.6%$166.52MN/A-1.2230Positive News
DERM
Journey Medical
1.8579 of 5 stars
$7.18
+0.6%
$9.50
+32.3%
+27.3%$166.33M$56.13M-18.4190
PBYI
Puma Biotechnology
4.1903 of 5 stars
$3.43
+3.0%
$7.00
+104.1%
+18.4%$165.27M$230.50M4.45200
DMAC
DiaMedica Therapeutics
0.903 of 5 stars
$3.90
+1.6%
$8.00
+105.1%
+27.1%$164.67MN/A-6.0920
SPRO
Spero Therapeutics
3.8908 of 5 stars
$2.90
-1.4%
$5.00
+72.4%
+124.4%$164.38M$47.98M-2.27150

Related Companies and Tools


This page (NASDAQ:HOWL) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners